CE Mark for CeQur insulin delivery device

HORW, Switzerland – European regulators have awarded CE Mark approval to CeQur for its PaQ? insulin delivery device, a discreet, wearable device that provides three days of consistent basal insulin delivery and easy, on-demand bolus insulin for type 2 diabetes patients.

The small device consists of a disposable insulin-infuser reservoir attached to a reusable insulin monitor. It easily attaches to the patient’s abdominal area with a safe and secure adhesive backing. Insulin is delivered subcutaneously through a fine, soft tube or cannula from the reservoir, which the patient changes every few days.

 “This regulatory achievement demonstrates the quality of both the PaQ device and the internal processes we’ve put in place to move this unique, important product through development and into the marketplace,” said James Peterson, founder and CEO, CeQur.